Medico Research Chronicles
Molecular alterations, immune microenvironment, and prognostic biomarkers in diffuse large b-cell lymphoma: A systematic review and meta-analysis
Door Dr. Harshit Kantilal Patel, Dr. Priyanka Rameshbhai Thakor en Dr. Vishwas Bhai Chhagan Bhai Bed.
Inhoud in het Engels
Abstract
Background
Diffuse large B-cell lymphoma (DLBCL) is biologically heterogeneous, and about one-third of patients are not cured with rituximab-based chemoimmunotherapy.
Methods
Following PRISMA 2020, PubMed/MEDLINE and PubMed Central were searched (2008–2025) for primary cohorts of de novo DLBCL reporting OS hazard ratios (HRs) with 95% confidence intervals (CIs) for MYC/BCL2 protein double expression (DE), TP53 mutation, tumour-cell PD-L1 expression, CD163+ M2 tumour-associated macrophages (TAMs) and non-germinal-centre B-cell (non-GCB)/activated B-cell (ABC) cell of origin (COO). The review is registered in PROSPERO (CRD420261530104).